High-dose daunorubicin in older patients with acute myeloid leukemia.
By B. Löwenberg, G. Ossenkoppele, W. van Putten, H. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen‐Lavrencic, M. von Lilienfeld-Toal and 9 more. New England Journal of Medicine, 2009
813 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/f0172adb14e5664a8c6a8692c974abf2c7152449
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Therapeutic advances in acute myeloid leukemia. (2011, neutral): “The traditional dose level of daunorubicin has recently been challenged in a large randomized study.(13) Doubling the dose of daunorubicin (90 mg/m(2) for 3 days) in a single cycle, did not increase”
- Acute myeloid leukemia: current progress and future directions (2021, background): “(6) The addition of the BCL-2 inhibitor venetoclax to induction therapy on investigational trials.”